Cardiovascular health, heart failure, atherosclerosis, and cardiac research
460 articles
A completed registry study identified and genotyped HoFH patients with LDLR mutations, laying groundwork for targeted gene therapy.
Akeso's AK102 faces a placebo-controlled test in high-cardiovascular-risk patients already on statins and ezetimibe.
A completed Phase IIIb trial tests whether pelacarsen can safely lower Lp(a) in historically underrepresented cardiovascular disease populations.
A 3-month interval cycling program assessed cardiovascular and metabolic improvements in obese vs. normal-weight women.
Experts propose that structured anticoagulation services offer a blueprint for broader cardiovascular medication stewardship programs.
A formal correction is issued to the landmark 2025 multi-society hypertension guidelines, ensuring clinical accuracy for practitioners.
A correction to a landmark study linking breast cancer to latent BMPR2-driven pulmonary hypertension susceptibility in Circulation.
A landmark 8,500-patient trial challenges 40 years of cardiology practice, finding beta blockers unnecessary after uncomplicated heart attacks.
A landmark Phase 3 trial evaluates whether omecamtiv mecarbil, a cardiac myosin activator, reduces cardiovascular death in HFrEF patients.
A phase 3 trial adding ERN/LRPT to statin therapy for dyslipidemia was terminated early, raising questions about the drug's clinical future.
A newly discovered protein called HELZ2 controls how much harmful cholesterol the liver releases, opening a fresh path to heart disease treatment.
A Phase 1 trial examines if the triple-agonist GLP-1 drug retatrutide changes how the body processes the beta-blocker metoprolol.
